{
    "nct_id": "NCT04788043",
    "official_title": "A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma",
    "inclusion_criteria": "* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n* Biopsy proven relapsed or refractory cHL\n* Prior treatment with at least two systemic therapies\n* Metabolically active measurable disease by PET imaging per the 2014 Lugano criteria\n* Hemoglobin ≥ 9.5 g/dL\n* Absolute neutrophil count ≥ 1,000 cells/μL without G-CSF support within 3 weeks prior to enrollment\n* Platelet count ≥ 75,000 cells/μL\n* Creatinine clearance > 40 mL/min per the Cockroft-Gault formula\n* Total bilirubin < 1.5 x upper limit of normal (ULN) (or < 3.0 x ULN and primarily unconjugated in subjects with a history of Gilbert's syndrome)\n* Negative urine or serum pregnancy test within 30 days of enrollment and within 72 hours before the first administration of magrolimab for women of childbearing potential\n* Women of childbearing potential must be willing to use at least 1 highly effective method of contraception during the study and continue for 4 months after the last dose of magrolimab\n* Male subjects who are sexually active with a woman of childbearing potential and who have not had vasectomies must be willing to use a barrier method of contraception during the study and for 4 months after the last dose of magrolimab\n* Ability to understand and the willingness to sign the written IRB approved informed consent document\n* Must be willing and able to comply with the clinic visits and procedures outlined in the study protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a PD-1 inhibitor within 3 months prior to enrollment\n* Prior treatment with antibodies targeting CD47 or SIRPα2\n* Prior allogeneic hematopoietic cell transplantation\n* Systemic autoimmune disorder on chronic immunosuppression (defined as ≥ 10 mg of prednisone daily)\n* RBC transfusion dependence, defined as requiring more than 2 units of RBCs during the 4-week period prior to screening\n* History of hemolytic anemia, autoimmune thrombocytopenia, or Evan's syndrome within the last 3 months\n* Second malignancy not in complete remission for at least 1 year, excluding fully resected non melanoma skin cancer or localized prostate cancer\n* Women who are pregnant or breast feeding\n* HIV or hepatitis B or C infection with active viral replication by PCR\n* Second malignancy not in complete remission for at least 1 year, excluding fully resected non-melanoma skin cancer or localized prostate cancer\n* Active cardiac disease including unstable angina, decompensated congestive heart failure, or severe uncontrolled conduction abnormalities\n* History of non-infectious pneumonitis requiring corticosteroids or current pneumonitis\n* Significant medical conditions, as assessed by the investigators and IND holder, that would substantially increase the risk benefit ratio of participating in the study\n* History of psychiatric illness or substance abuse likely to interfere with ability to comply with protocol requirements\n* Received a live or live attenuated vaccine within 30 days before the first dose of study intervention\n* Received any anti-cancer therapy within 2 weeks prior to the first dose of study intervention",
    "miscellaneous_criteria": ""
}